Relation of Periprocedural Bleeding Complications and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)

American Journal of Cardiology

Volumn 103, Issue 7, 2009, Pages 917-922

  Brugts, Jasper Jan ^a   Mercado, Nestor ^b   Hu, Stephen ^b   Guarneri, Mimi ^b   Price, Matthew ^b   Schatz, Richard ^b   Teirstein, Paul ^b   Wijns, William ^c   Serruys, Patrick W ^a   O'Neill, William W ^d   Boersma, Eric ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SCRIPPS CLINIC   (United States)

^c OLV HOSPITAL   (Belgium)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

XEMILOFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BENZAMIDINES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; RISK FACTORS; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 63049091023     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.12.017     Document Type: Article

References (15)

1. O'Neill W.W., Serruys P., Knudtson M., van Es G.A., Timmis G.C., van der Zwaan C., Kleiman J., Gong J., Roecker E.B., Dreiling R., Alexander J., and Anders R. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 342 (2000) 1316-1324
2. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Mahaffey K.W., Moliterno D.J., Lincoff A.M., Armstrong P.W., Van de Werf F., Califf R.M., and Harrington R.A. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47 (2006) 809-816
3. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., Mahaffey K.W., Califf R.M., and Harrington R.A. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96 (2005) 1200-1206
4. Feit F., Voeltz M.D., Attubato M.J., Lincoff A.M., Chew D.P., Bittl J.A., Topol E.J., and Manoukian S.V. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 100 (2007) 1364-1369
5. Manoukian S.V., Feit F., Mehran R., Voeltz M.D., Ebrahimi R., Hamon M., Dangas G.D., Lincoff A.M., White H.D., Moses J.W., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
6. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., and Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114 (2006) 774-782
7. Ndrepepa G., Berger P.B., Mehilli J., Seyfarth M., Neumann F.J., Schömig A., and Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
8. Dauerman H.L. Percutaneous coronary intervention pharmacology from a triangle to a square. J Am Coll Cardiol 51 (2008) 698-700
9. Cho L., Topol E.J., Balog C., Foody J.M., Booth J.E., Cabot C., Kleiman N.S., Tcheng J.E., Califf R., and Lincoff A.M. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 36 (2000) 381-386
10. Chen M., Bhatt D., Chew D., Moliterno D., Ellis D., and Topol E. Outcomes in African Americans and whites after percutaneous coronary intervention. Am J Med 118 (2005) 1019-1025
11. Yang X., Alexander K.P., Chen A.Y., Roe M.T., Brindis R.G., Rao S.V., Gibler W.B., Ohman E.M., Peterson E.D., and CRUSADE Investigators. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46 (2005) 1490-1495
12. Rao S.V., Jollis J.G., Harrington R.A., Granger C.B., Newby L.K., Armstrong P.W., Moliterno D.J., Lindblad L., Pieper K., Topol E.J., Stamler J.S., and Califf R.M. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
13. Jozic J., Steinhubl S.R., Dangas G.D., Hooper W.C., and Stone G.W. Markers of inflammation and their changes over time in relationship to clinical outcomes and therapeutic interventions in the acute coronary syndrome patient: results from the ACUITY inflammation sub-study. Am J Cardiol 98 suppl (2006) 36M
14. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
15. Steinberg D.H., Shah P., Kinnaird T., Pinto Slottow T.L., Roy P.K., Okabe T., Bonello L., de Labriolle A., Smith K.A., Torguson R., et al. Bleeding risk and outcomes of bivalirudin versus glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Am J Cardiol 102 (2008) 160-164